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ABSTRACT
Previously, antihypertensive treatment in severe aortic stenosis was considered a relative 
contraindication. However, recent studies have shown that antihypertensive treatment may 
be safe and even beneficial in terms of reducing the progression of left ventricular pressure 
overload and even retarding the progression of valvular aortic stenosis. To date, no randomized 
clinical trials have been performed and no definite treatment guideline exist for the proper 
antihypertensive regimens. Antihypertensive treatment with β-blockers has generally been 
avoided in patients with severe aortic stenosis (AS) due to the concerns for inducing left 
ventricular dysfunction and hemodynamic compromise in the presence of severe outflow tract 
obstruction. Although it remains unclear whether antihypertensive treatment with a β-blocker 
is associated with increased risk of cardiovascular events in patients with AS, recent studies have 
shown that the use of β-blockers may be safe and may even be beneficial. Renin-angiotensin 
system (RAS) are upregulated in AS and have been shown to be involved in valve calcification 
and progression in both experimental models and in human trials. As such, theoretically, RAS 
inhibition would have benefit in retarding the progression of valvular stenosis as well as have 
benefit in left ventricle remodeling. Recent clinical studies are indeed showing that use of RAS 
inhibition may be beneficial in patients with AS. Future clinical trials to establish the ideal target 
blood pressure and antihypertensive regimens in severe AS is essential.
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INTRODUCTION
The prevalence of calcific aortic valve stenosis (AS), increases with age.1)2) As such, there are 
up to 50% prevalence of hypertension in subjects with AS.3) The presence of hypertension 
may increase the risk of cardiovascular disease as well as accelerate the progression of aortic 
stenosis. In the recently published PROGRESSA study, hypertension was shown to accelerate 
the progression of aortic valve calcification in patients with aortic stenosis.4) Also, patients 
with AS are already burdened by excess pressure overload to the left ventricle (LV) due to the 
stenotic aortic valve. Hypertension, by increasing the systemic vascular load will add to the 
already increased after load with subsequent deleterious effect on hypertrophic remodeling 
LV systolic/diastolic function with subsequent worsening of clinical outcomes.5-7) However, 
antihypertensive treatment in severe AS has been thought of as a relative contraindication due 
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Antihypertensive Treatment in Severe 
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to the concern that antihypertensive treatment, due to the presence of fixed obstruction in the 
aortic valve, may cause excessive peripheral vasodilation and decrease in coronary blood flow, 
resulting in hypotension and hemodynamic collapse. Recently, studies have shown that these 
concerns are not supported by clinical practice and that antihypertensive treatment may in fact 
be needed to improve LV remodeling and ultimately improve the prognosis. Accordingly, recent 
clinical practice guidelines recommend that hypertension be treated in patients with AS.8)
Systemic hypertension aggravates the total LV pressure overload that is already at a tipping point 
in patients with severe aortic stenosis. As such, antihypertensive treatment is needed to reduce 
the LV pressure overload. Antihypertensive treatment with severe AS patients should be started 
at low doses with careful titration. It should also be emphasized that hypertension can interfere 
with the accurate assessment of AS severity and that valve and LV hemodynamics should be re-
evaluated after optimal blood pressure control in hypertensive patients with severe AS.
The main objectives of this review are to briefly review how hypertension adversely affect 
the progression of AS and review the current evidence regarding the potential benefits of 
antihypertensive treatment both before and after aortic valve replacement (AVR).
HYPERTENSION AND PROGRESSION OF AORTIC STENOSIS
Despite the knowledge that hypertension is an important medical problem that requires 
effective treatment to reduce cardiovascular morbidity and mortality, there has been 
reluctance to treat hypertension in patients with severe AS.9) The possibility of severe 
hypotension and hemodynamic collapse with peripheral vasodilation in the setting of a fixed 
cardiac output was a real concern. Also, there was a concern that the possibility of diastolic 
hypotension and the subsequent reduction in coronary blood flow will have deleterious 
effects, especially when considering that many of these patients are predisposed to increased 
risk of myocardial ischemia under conditions of increased myocardial oxygen demand.10) 
Recent studies have shown data to refute these old concerns. Hypertension, by increasing 
the afterload, accelerates the progression of AS and LV hypertrophy and has been shown 
to be an independent predictor for adverse cardiovascular outcomes.11-13) In the post hoc 
analysis from the SEAS trial (Simvastatin and Ezetimibe in Aortic Stenosis), the mortality 
rate was increased in subjects with asymptomatic AS who had average follow up systolic 
blood pressure (SBP) of ≥ 160 mmHg with SBP 130-139 mmHg taken as reference. However, 
there was a J-shaped association between blood pressure and outcomes with blood pressure 
of 130 to 139/70 mmHg being associated with the lowest outcomes.11) This data suggests that 
although hypertension adversely affects the prognosis of AS, too much lowering (average SBP 
< 120 mmHg) may have deleterious effects. Future clinical trials to establish the ideal target 
BP in AS is needed.
SAFETY AND POTENTIAL BENEFITS OF RENIN-
ANGIOTENSIN SYSTEM INHIBITION IN SEVERE AORTIC 
STENOSIS
Renin-angiotensin system (RAS) are upregulated in AS and have been shown to be involved in 
valve calcification and progression in both experimental models and in human trials.10)14)15) As 
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such, theoretically, RAS inhibition would have benefit in retarding the progression of valvular 
stenosis as well as have benefit in LV remodeling. Recent clinical studies are indeed showing 
that use of RAS inhibition may have clinical benefit in patients with severe AS.
In a retrospective analysis of 123 patients who underwent 2 serial electron beam computed 
tomographic scans, the use of angiotensin converting enzyme (ACE) inhibitors, compared 
to non ACE inhibitor group, was associated with significant lower rate of aortic valve calcium 
accumulation.15) In a recent post hoc analysis of the SEAS study, Bang et al.16) showed that 
RAS inhibition was not associated with sudden cardiac death, cardiovascular or all-cause 
mortality in asymptomatic AS patients. In fact, RAS inhibition was associated with a 
potentially beneficial effect in blood pressure and reduction in LV mass progression. Several 
small randomized trials have evaluated the efficacy of RAS inhibition in AS. SCOPE-AS 
(Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis) randomized 
56 patients with symptomatic severe AS to ACE inhibitor. This study demonstrated that 
enalapril was associated with improvement of the functional class and 6-minute walking 
distance after 4 and 12 weeks of follow-up.17) Dalsgaard et al.18) randomized 44 patients with 
severe symptomatic AS referred for AVR to trandolapril. They revealed that the ACE inhibitor 
group showed significant decreased SBP and increased systemic arterial compliance. 
The RIAS trial (Ramipril in Aortic Stenosis) randomized 96 patients with asymptomatic 
moderate or severe AS with preserved LVEF to either ramipril or placebo.19) It showed that 
ACE inhibition reversed LV hypertrophy (p = 0.0057). Ramipril also had trend to slow the 
progression of AVA decrease (0.0 versus −0.2 cm2/y; p = 0.067) and the rate of increase in peak 
velocity (0.03 versus 0.12 m·s−1·y−1; p = 0.28).
With regards to angiotensin receptor blockers (ARBs), there are paucity of data with regards 
to their efficacy in AS compared to ACE inhibitors. Theoretically, as non ACE pathway such 
as chymase activation are increased in the aortic valves and angiotensin II type 1 receptors are 
increased in the aortic valves, ARBs may have benefit comparable to ACE inhibitors in patients 
with AS with a retrospective study suggesting that ARBs are more effective than ACE inhibitors 
at reducing aortic valve calcium and LV remodeling.20) However, more data is needed whether or 
not ARBs have beneficial effects comparable to ACE inhibitors in patients with AS.
Although we will need evidence from larger, randomized outcome studies, recent data 
suggests the benefit of RAS inhibitors, especially ACE inhibitors in patients with AS. 
Therefore, ACE inhibitors are likely the preferred agents for treating hypertension with 
careful titration and dosage to avoid hypotension (Figure 1).
SAFETY AND POTENTIAL BENEFITS OF BETA BLOCKERS 
IN SEVERE AORTIC STENOSIS
Antihypertensive treatment with β-blockers has generally been avoided in patients with 
severe AS due to the concerns for inducing LV dysfunction in the presence of severe outflow 
tract obstruction. Although it remains unclear whether antihypertensive treatment with a 
β-blocker is associated with increased risk of cardiovascular events in patients with AS, recent 
studies have shown that the use of β-blockers are safe and may even be beneficial.
In a post hoc analysis of the SEAS trial, 932 of subjects (50%) received beta blockers at 
baseline. During a median follow up duration of 4 years, β-blocker was associated with 
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lower risk of all-cause mortality, cardiovascular death and sudden cardiac death.21) Also, in 
a retrospective analysis of 113 subjects with symptomatic, severe AS who did not undergo 
surgery, the use of β-blocker was associated with 62% reduction in all-cause mortality.22) The 
benefit of β-blocker may be due to their potential benefits in terms of reducing hemodynamic 
and metabolic overload in AS. In a study by Hansson et al.23), 40 patients with moderate-
severe asymptomatic AS (aortic valve area, 0.5 ± 0.1 cm2/m2; peak gradient, 53 ± 19 mmHg) 
were randomized to placebo or metoprolol treatment for 22 weeks. Metoprolol (100 ± 53 
mg/d), compared with placebo, significantly decreased the heart rate by −8 beats per minute 
(−13, −3; p = 0.003) and increased the systolic ejection time by 26 ms (2, 50; p = 0.03). 
Moreover, metoprolol reduced both the aortic valve peak −7 mmHg (−13, 0; p = 0.05) and 
mean −4 mmHg (−7, −1; p = 0.03) pressure gradients without having any significant effects 
on stroke volume. The valvuloarterial impedance and myocardial oxygen consumption 
were reduced by −11% and −12% (p = 0.03 and 0.01), respectively. The decrease in heart 
rate by metoprolol was significantly associated with lower valvuloarterial impedance, 
myocardial oxygen consumption, and improved myocardial efficiency, defined as stroke 
work/myocardial oxygen consumption (r = 0.63–0.65; all p < 0.01).23) Thus, the results from 
the above mentioned studies suggest that β-blockers may have beneficial hemodynamic and 
metabolic effects and may potentially be favorable in improving the outcome of patients with 
asymptomatic moderate-severe AS patients (Table 1).
In AS that are associated with significant aortic regurgitation (AR), the use of beta blockers, 
by increasing the diastolic filling period, potentially increase the severity of the valve 
regurgitation. As such, the recent 2017 ACC/AHA/ASH hypertension guideline recommends 
not to use beta blockers in chronic aortic insufficiency.24) Despite these theoretical concerns, 
there are no evidence that beta blockers are harmful in AR. On the contrary, in a double 
blind, randomized study in 75 asymptomatic patients with moderate to severe AR, treatment 
with controlled release metoprolol for 6 months had no significant effect on LV volumes.25) 
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Hypertension with severe aortic stenosis
BP goal not met
BP goal not met
Beta-blocker (except atenolol) titration*
(Start at half the usual dose with slow titration) 
Calcium channel blocker or diuretics
with careful titration
* Contraindication in case of moderate to severe AR combined
Target BP 130–140/90–70mmHg
RAS inhibition with titration
(Start at half the usual dose with slow titration)
Figure 1. Algorithm of antihypertensive treatment of severe aortic stenosis. AR: aortic regurgitation, BP: blood 
pressure, RAS: renin-angiotensin system.
Lastly, β-blocker are the preferred antihypertensive agents in patients with hypertension and 
thoracic aortic aneurysm, which are frequently associated with AS.24)
The above mentioned results suggest that beta blockers may have beneficial hemodynamic 
effects in AS and may be improve the clinical outcome in patients with severe AS. However, 
the results should be confirmed in future prospective, randomized trials.
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Table 1. Summary of clinical studies of antihypertensive treatment in aortic stenosis






AVA < 0.75 cm2, mean aortic 
gradient > 50 mmHg, or 
aortic valve Doppler jet > 4.5 
m/s; NYHA functional class 
≥ III/IV or angina




Enalapril demonstrated significant 
improvement in NYHA class, Borg 
dyspnea scale (5.4 ± 1.2 vs 5.6 ± 1.7, 
p = 0.03), and 6-min walk distance 
(402 ± 150 vs 376 ± 174, p = 0.003)
Enalapril was tolerated without 
hypotension or syncope






80 patients control vs 43 
received ACEI AVC by CT scan
Adjusted odds ratio (95% CI) 
for definite AVC progression was 
significantly lower in ACEI group 





Observational Prospectively collected in 





not treated by RAS 
inhibition, treated 
with ACEI, ARB
Patients in hypertension group: 
faster stenosis progression 
(p = 0.01), patients on ARBs: slower 
AS progression compared with other 
groups
Hypertension (HR: 2.45; 
p = 0.006) and ACEI (HR: 2.30; 
p = 0.01) groups: significant 
increase in all-cause mortality 
compared with control group
6.2 ± 2.4 years follow up
Dalsgaard 




Severe symptomatic AS 
referred for AVR
Trandolapril 
(n = 22) 
vs placebo 
(n = 22)
Significant decrease in systolic BP 
and increase in systemic arterial 
compliance in ACEI group
No episodes of symptomatic 
hypotension. Other hemodynamic 
parameters remained unchanged.For 3 days
Bang 




n=769 in SEAS3) RAS inhibitor SCD (HR: 1.19, 95% CI: 0.50–2.83, 
p = 0.694), CV (HR: 1.05, 95% CI: 
0.62–1.77, p = 0.854) or all-cause 
mortality (HR: 0.81, 95% CI: 
0.55–1.20, p = 0.281)
Larger reduction in systolic blood 
pressure (p = 0.001) and less 
progression of LV mass 
(p = 0.040).
AS and preserved LVEF
4.3 ± 0.9 years follow up




Asymptomatic AS with AVA 
< 1.5 cm2 or peak velocity 
> 3.0 m/s and LVEF > 50%




ACEI reversed LV hypertrophy 
(p = 0.0057). Slow the progression 
of AVA decrease (0.0 vs−0.2 cm2/y; 
p = 0.067) and the rate of increase in 
peak velocity (0.03 vs 0.12 m·s−1·y−1; 
p = 0.28)
There were no differences in 
the progression to AVR or major 
adverse clinical events between 
the two groups1 year follow up
Beta blocker
Rossi 
et al22)  
(2015)
Retrospective Excluded candidate for AVR, 
severe AS with symptomatic 
EuroSCORE 30 ± 20
BB use vs control BB group: lower mortality risk 
compared to patients without BBs 
(HR: 0.35, 95% CI: 0.16–0.679, 
p = 0.01)
Effect of BBs: similar in patients 
irrespective of whether they 
underwent BAV (HR: 0.38, 95% CI: 
0.13–0.10, p = 0.07) or not 
(HR: 0.36, 95% CI: 0.10–1.21, 
p = 0.09)
mean 10 ± 10 months
Hansson 






(aortic valve area, 0.5 ± 0.1 
cm2/m2; peak gradient, 53 ± 
19 mmHg)
Metoprolol 
(100 ± 53 mg/d) 
vs placebo
Metoprolol: heart rate of −8 beats 
per minute (−13, −3; p = 0.003), 
increased the systolic ejection time 
26 ms (2, 50; p = 0.03) and reduced 
AV peak −7 mmHg (−13, 0; p = 0.05) 
and mean −4 mmHg (−7, −1; 
p = 0.03) PG
Valvuloarterial impedance and 
myocardial oxygen consumption 
were reduced by −11% and −12% 
(p = 0.03 and 0.01)
22 weeks follow up
Bang 




n=1873 in SEAS3) BB use vs control BB: lower risk of all-cause mortality 
(HR: 0.5, 95% CI: 0.3–0.7, p < 0.001)
CV death (HR: 0.4, 95% CI: 
0.2–0.7, p < 0.001), and SCD 
(HR: 0.2, 95% CI: 0.1–0.6, 
p = 0.004)
mild to moderate AS and 
preserved LVEF
4.3 ± 0.9 years
ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, AS: aortic stenosis, AVA: aortic valve area, AVC: aortic valve calcification, AVR: 
aortic valve replacement, BAV: balloon aortic valvuloplasty, BB: beta blocker, BP: blood pressure, CI: confidence interval, CV: cardiovascular, HR: hazard ratio, 
LVEF: left ventricular ejection fraction, NYHA: New York Heart Association, PG: pressure gradient, RAS: renin angiotensin system, SCD: sudden cardiac death.
EFFECT OF VASODILATION ON HEMODYNAMICS IN 
SEVERE AORTIC STENOSIS
Vasodilator therapy is a cornerstone in the management of patients with LV dysfunction. 
However, vasodilators were traditionally contraindicated in patients with severe AS due to 
concerns that they may precipitate life-threatening hypotension.
However, recent studies have demonstrated the beneficial effects of vasodilatation and 
afterload reduction in patients with severe AS with heart failure. The Use of Nitroprusside 
in Left Ventricular Dysfunction and Obstructive Aortic Valve Disease (UNLOAD) Study26) 
investigated the usefulness of nitroprusside in intensive care unit patients with depressed 
heart function (ejection fraction < 35%), cardiac index (< 2.2 L/min per square meter), and 
severe AS (aortic valve area < 1.0 cm2). At baseline, the mean (SD) ejection fraction was 
0.21 ± 0.08, aortic valve area was 0.6 ± 0.2 cm2, and peak and mean gradients were 65 ± 37 
mmHg and 39 ± 23 mmHg, respectively. After 24 hours of nitroprusside infusion, the cardiac 
index increased to 2.52 from a baseline of 1.6 L/min/m2 with minimal side effect. This study 
demonstrated that nitroprusside rapidly and markedly improves cardiac function in patients 
with decompensated heart failure due to severe LV systolic dysfunction and AS and indicates 
that afterload reduction with arterial vasodilation may improve the hemodynamics of severe 
AS with reduced ejection fraction with minimal side effects. However, the beneficial effect 
of after load reduction with RAS inhibitors for a longer duration in severe AS with reduced 
ejection fraction needs to be confirmed in future clinical trials.
More recently, Eleid et al.27) reported invasive hemodynamic analysis of hypertensive 
patients with symptomatic low gradient severe AS with preserved ejection fraction who 
were administered nitroprusside infusion. Nitroprusside infusion was associated with 
improvement in mean pulmonary artery pressure and LV end diastolic pressure while 
increasing the aortic valve area and mean pressure gradient. Hypertension is frequently 
associated with low gradient severe AS and may be a factor to overestimate the severity of 
the degree of AS.28) Lloyd et al.29) reported that nitroprusside reduces afterload and LV filling 
pressures in patients with low-gradient severe AS and preserved ejection fraction, enabling 
reclassification to moderate stenosis in 25% of patients. Therefore, in asymptomatic low 
pressure gradient severe AS patients with associated hypertension, initial treatment of 
hypertension may result in down classification of the severity of the aortic stenosis and allow 
for medical treatment in some of these patients.
TREATMENT OF HYPERTENSION AFTER AORTIC VALVE 
REPLACEMENT
Surgical AVR, including transcatheter aortic valve replacement (TAVR), are the definite 
treatments of choice for symptomatic severe aortic stenosis. However, technically successful 
procedure and the associated reduction in the severity of aortic valve obstruction will not 
automatically guarantee optimal clinical outcomes. Large, randomized trials and registries 
consistently showed a high rate of readmission despite successful and uncomplicated AVR.30) 
Some data suggest that LV mass regression and abnormal LV and left atrial strain may persist 
beyond 2 years after AVR and may be related in recurrent episodes of heart failure.30)31) In an 
analysis of 105 patients who underwent TAVR, 51% of the subjects had increase in their blood 
pressure requiring intensification of antihypertensive treatment. This suggests that effective 
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treatment of hypertension may be crucial to optimize the prognosis of patients undergoing 
surgical or TAVR.32)
Previous studies have demonstrated that ARB after AVR for severe AS has beneficial effect in 
terms of reverse remodeling compared to conventional management. In a study by Dahl et al.33), 
114 subjects who underwent AVR were randomized to either candesartan 32 mg or conventional 
therapy immediately after surgery. The results showed that mean decrease in LV mass index in 
the control group was 12 ± 28 g/m2 compared to 30 ± 40 g/m2 in the candesartan group (p = 0.015) 
during follow-up. After 12 months LV mass index was significantly lower in the candesartan 
group (103 ± 29 vs 119 ± 31 g/m2, p = 0.01). In another retrospective observational study, Goel et 
al.34) analyzed 741 patients who were prescribed RAS inhibitors with 1011 patients who did not 
receive any RAS inhibitors after surgical AVR between 1991 and 2000 in a single tertiary center. 
They found that subjects prescribed RAS inhibitors after surgery for at least 6 months were 
associated with increased survival rates. However, the benefit of RAS inhibitors in hypertensive 
patients in AS patients after AVR must be confirmed in future clinical outcome studies.
CONCLUSION
Antihypertensive treatment in severe AS is safe and may be important for reducing the 
LV pressure overload and retarding the progression of severe valvular aortic stenosis. To 
date, no randomized clinical trial has been performed and no definite treatment guideline 
for antihypertensive regimens. However, RAS inhibitors and β-blockers are safe may be 
beneficial in these patients. Based on these observations, we summarized the current 
available data into a treatment algorithm (Figure 1). Future clinical trials to establish the ideal 
target BP and antihypertensive regimens in severe AS is essential.
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